Navigation Links
QCDx Announces Sale of the RareScope to the Carole and Ray Neag Comprehensive Cancer Center at UConn Health for Use in Clinical Research
Date:1/22/2020

QCDx, a private biotech company that has developed a breakthrough Circulating Tumor Cell (CTC) liquid biopsy from a simple blood draw, today announced the sale of the proprietary RareScope™ instrument to the Carole and Ray Neag Comprehensive Cancer Center at UConn Health. The Rare Scope will be used in clinical cancer research.

“The RareScope can detect and isolate intact and live Circulating Tumor Cells from a blood sample of a cancer patient after analyzing every single nucleated cell,” said Dr. Pramod K. Srivastava PhD MD, Director of the Carole and Ray Neag Comprehensive Cancer Center at UConn Health and a world authority in cancer immunology. “We intend to use the ability of the RareScope to obtain a deep look into the genomes of cancer cells in patients undergoing standard-of-care and experimental treatments.”

“We are proud that the Carole and Ray Neag Comprehensive Cancer Center at UConn Health has selected the RareScope as the optimal method to detect and immunologically characterize CTCs from patients in clinical studies of personalized therapeutics with potential to cure metastatic cancer,” said Dr. Triantafyllos (Fyl) Tafas, Founder and CEO of QCDx. “Our technology tackles the ultimate challenge presented by cancer continually changing in the patient’s body and often becoming resistant to a chosen therapy. With sensitive CTC detection and characterization, we aim to reveal early indications of disease progression and new molecular targets that can be used for real-time, personalized treatment.”

About CTC Liquid Biopsy:
Cells from solid tumors enter the blood stream very early in the tumor development, become CTCs and eventually cause metastasis. Tumors are heterogeneous and CTCs reflect their different genetic profiles. Today, the standard practice for solid cancers detection are biopsies, which are invasive, cannot be used repeatedly and are ineffective in metastatic disease and assessing treatment effectiveness. CTC liquid biopsies from a simple blood draw can be repeated frequently to reveal the disease heterogeneity. The ultimate CTC diagnostic engine must accurately detect and characterize different CTC phenotypes from the original tumor and potential, metastatic sites. Additionally, isolate intact and live CTCs for downstream genomic, transcriptomic, epigenetic and other molecular analyses that can provide guidance for personalized and timely cancer treatment.

About UConn Health:
UConn Health is Connecticut’s only public academic medical center. Based on a 206-acre campus in Farmington, UConn Health has a three-part mission: research, teaching and patient care. Home to the UConn School of Medicine, School of Dental Medicine and UConn John Dempsey Hospital with nearly 5,000 employees supporting nearly 1,000 students, over 800,000 annual patient visits, and innovative scientific research contributing to the advancement of medicine. For more information, visit health.uconn.edu.

About QCDx:
QCDx develops, manufactures and markets tools and integrated systems to detect and monitor cancer at the single cell level. Our technology provides innovative solutions for analyzing all nucleated cells within a blood sample, in an immobilized, multi-million cell suspension, detects intact and live CTCs and isolates for downstream, single-cell molecular analyses. Our technology and products aim to accelerate cancer research and treatment and ultimately transforming healthcare.

For more information, visit http://www.qcd-x.com.

Stay in touch on LinkedIn.

Read the full story at https://www.prweb.com/releases/qcdx_announces_sale_of_the_rarescope_to_the_carole_and_ray_neag_comprehensive_cancer_center_at_uconn_health_for_use_in_clinical_research/prweb16845956.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology technology :

1. Vuja De Sciences Announces the Appointment of Two New Board Members
2. ABCT, Connecticut’s Newest Accelerator Program for Biosciences Ventures, Announces 2020 Cohort of Life Science Startups
3. Leak Detection Associates Announces New SIMS 21 CFR Part 11 Compliant System Software
4. Leak Detection Associates Announces New SIMS 1915+ Low Temperature -80C Helium Leak Testing System
5. Silony Medical Announces First Robotic Assisted Surgery in the UK
6. Cirrascale Cloud Services Announces Availability of Graphcore IPU Servers and Cloud Instances for Machine Intelligence Workflows
7. DermBiont Announces Positive Data from Phase 2a Clinical Trial and Start of Phase 2b Clinical Trial for Athlete’s Foot with a Topical Live Biotherapeutic
8. R3 Stem Cell Announces Addition of World Renowned Exosome Expert Dr. Ian White to Training Course
9. Cereset® Announces Mild-Traumatic Brain Injury Focused Clinical Trial Progress
10. Personalized Stem Cells, Inc. Announces Clinical Trial Sites Qualified for FDA Approved Clinical Trial for Treatment of Osteoarthritis with Stem Cells
11. Advancements Announces New Episode Focusing on Innovations in Health, Medicine, and Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2020)... ... February 05, 2020 , ... Rare Disease Day® , ... The National Organization for Rare Disorders (NORD), to raise awareness amongst the general public ... The Balancing Act’s “Behind The Mystery” rare disease series will be ...
(Date:1/28/2020)... WORTH, Texas (PRWEB) , ... January 28, 2020 ... ... Scientific to be the exclusive distributor to food and beverage manufactures within ... and are considered critical suppliers. This agreement will allow each company to pool ...
(Date:1/27/2020)... ... January 27, 2020 , ... Cerebyte, the leader in “instant ... today announced the availability of neuroscience of transformational leadership workshops. These highly interactive, ... of leadership and change research to become great transformational leaders. The workshops ...
(Date:1/24/2020)... ... January 24, 2020 , ... ... companies in biotechnology, diagnostics, therapeutics, laboratory and clinical services during the first two ... around the world. And as Slone Partners celebrates its 20th anniversary ...
Breaking Biology Technology:
(Date:1/29/2020)... ... January 29, 2020 , ... VGXI, ... start production of a DNA vaccine against the novel coronavirus (2019-nCoV) that has ... grant of up to $9 million from the Coalition for Epidemic Preparedness Innovations ...
(Date:1/28/2020)... ... 28, 2020 , ... Blue Health Intelligence (BHI) published an ... care, and limit the utilization of high-cost imaging and surgeries for musculoskeletal (MSK) ... Texas specializes in improving care delivery for MSK conditions. In an independent study ...
(Date:1/27/2020)... ... January 27, 2020 , ... Cytonus Therapeutics Inc. today announced ... entrepreneur, and former senior management consultant at McKinsey & Company who holds three ... investment firm. , “Chris Thorne has exceptional business acumen with a proven ...
Breaking Biology News(10 mins):